Table 1.
Summaries of proangiogenic metals and their signaling pathways.
| Metal | Mechanism of action |
Nanomaterial format |
Experimental methods |
Method of fabrication |
Nanomaterial concentrations tested |
References |
|---|---|---|---|---|---|---|
| Terbium | NADPH oxidase-mediated PI3K/AKT activation, ROS accumulation | Layered terbium(III) hydroxide (Tb(OH)3) nanorods, Tb(OH)3 nanospheres | Sprouting and proangiogenesis fluorescence by an in vivo zebrafish embryo assay | Reaction of aqueous terbium(III) nitrate hydrate and NH4OH with SINEO-MAS II, reaction of TbCl3 hydrate and NaCl/NaOH at 60°C | 5–10 μg/mL | [88]-[91] |
| Europium | PI3K/AMPK/Akt activation, inhibition of TNF-α and IL-6, upregulation of CD31 | Europium(III) hydroxide (Eu(OH)3) nanorods, Eu(OH)3 nanospheres | Sprouting and proangiogenesis fluorescence by an in vivo zebrafish embryo assay | Simple microwave heating of an aqueous solution of europium(III) nitrate and NH4H2PO4 | 20–50 μg/mL | [92]-[96], [125] |
| Cerium | Upregulation of HIF-1α, enhanced VEGF mRNA translation | Ce3+/Ce4+ containing oxide | In vitro endothelial tube formation assay, branch number measured by an in vivo CAM assay | Flame spray pyrolysis of cerium-containing liquid precursor and cerium 2-ethylhexanoate in xylene | 50 μg/mL | [97]-[99] |
| Copper | VEGF-A and FGF2 upregulation, enhanced expression of PCNA, MyoD1 | Copper hydrocolloid nanospheres | Vessel length and branch number measured by an in vivo CAM assay | Copper oxide impregnation of wound dressing fibers | 0.1–10 μM | [101], [104], [105] |
| Cobalt | Activation of AKT/ERK1/2, transcriptional activation of NF-κB, AP-1 and VEGF | Tungsten carbide-cobalt nanoparticles | VEGF secretion measured in vitro, neovascularization measured in vivo with HUVEC | Sol-gel method with tetraethyl orthosilicate, triethyl phosphate, Ca(NO3)2, and CoCl2, and nitric acid | 1,000–2,000 μg/mL | [106]-[108] |
| Zinc | ROS production, VEGF and FGF upregulation, ZnR/GPR39, Gq-PLC, and MAPK-Akt-eNOS activation | Zinc oxide (ZnO) nanoflowers, ZnO nanorods | Vessel branch number measured by an in vivo CAM assay | Sol-gel method with Zn(CH3COO)2 and albumin in ultrapure water | 10–50 μg/mL | [102], [109]-[111] |
| Nickel | Release of HIF-1, IL-6, c-IAP, BCL-2, ICAM-1, IL-1β, and Cox-2 | Nickel titanium nanoparticles | Measurement of angiogenic potential in athymic (T cell-deficient) nude mice | Prepared via laser evaporation of NiTi alloy, nanoparticles heat-treated at 250°C and resuspended in LAL reagent water | 0.25–0.75 mM | [12], [112] |
| Magnesium | MC3T3-E1 expression, PDGF-BB secretion | Mg2+ ions | Angiogenic potential measured by in vivo CAM assay, cytocompatibility measured in vitro with MC3T3-E1 | Hydroxyapatite and MgO added to sodium alginate solution, and extruded to CaCl2 | 1–5 mM | [103], [113]-[115] |
| Lithium | Augmentation of Wnt/β-catenin in Norrin/Frizzled-4, VEGF secretion through the phosphorylation of glycogen synthase kinase-3β (GSK-3β) | Li+ (in the form of LiCl) | In vitro measurement of proangiogenic factors (VEGF) secretion by BMSC | LiCl in serum-free medium | 0.2–20 mM | [116]-[119] |
| Cadmium | Enhanced VEGF expression, activation of PKB/Akt, NF-κB, MAPK, and ERK/AKT | Ultralow concentrations of elemental cadmium | In vitro measurement of endothelial structure formation with HUVEC | Cadmium chloride in basal media | 1–10 μM | [120]-[122] |
| Chromium | Enhance promoters for proangiogenic transcription factors such as NF-κB, p53, and c-Fos | Hexavalent chromium (Cr(VI)) compounds | In vitro measurement of proangiogenic miR-143 and miR-145 in Cr(VI)-transformed cells | Chromium nanomaterial in the form of Cr(VI) oxidation state | 1–10 μM | [123] |